Clinical trials: Avian Influenza
Influenza, Pandemic
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1014. BW-1014 is a nanoemulsion (NE) adjuvanted recombinant Hemagglutinin 5 (rH5) that would protect against pandemic flu.
- Trial name
- IN-NE-rH5 (NCT05397119)
- Testing
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- BlueWillow Biologics
Avian Influenza, H1N1 Influenza
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and…
- Conditions
- Avian Influenza, H1N1 Influenza, Influenza
- Trial name
- NCT02921997
- Testing
- AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days.
- Trial name
- NCT03283319
- Testing
- 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7
- Where
- 4 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Avian Influenza
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses…
- Trial name
- NCT02612909
- Testing
- IVACFLU-A/H5N1 vaccine
- Where
- 2 sites in Vietnam
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Influenza
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Background: Adjuvants are substances included in vaccines that stimulate the immune system and increase the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in Europe.
- Trial name
- NCT01578317
- Testing
- H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797…
- Trial name
- NCT02839330
- Testing
- aH5N1c
- Where
- 26 sites in United States
- Volunteers
- 3,196 people, healthy volunteers welcome
- Sponsor
- Seqirus
Avian Influenza, Influenza Immunisation
2013/2017 H7N9 Prime-Boost Interval
This is a trial designed to assess the safety, reactogenicity and immunogenicity of one or two doses of monovalent inactivated split influenza 2013 and 2017 A/H7N9 virus vaccines administered intramuscularly at different dosages…
- Trial name
- NCT03589807
- Testing
- A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
- Where
- 6 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infectious Diseases, Influenza
Development of Immune Globulin Treatment for Avian Flu
This study will determine how best to use a vaccine for generating high levels of antibodies called immune globulins (IVIG) in people, which, in turn, can be collected and used to develop a possible treatment for avian influenza…
- Conditions
- Infectious Diseases, Influenza, Avian Flu
- Trial name
- NCT00383071
- Testing
- H5N1 vaccine, Apheresis
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human, Influenza in Birds
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
This is a Phase 2, randomized, multi-center study in approximately 300 adults who received 2 doses of aH5N1c or placebo in and completed the parent study V89_18 in the <65 years of age cohort.
- Conditions
- Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections
- Trial name
- NCT05422326
- Testing
- aH5N6c on Day 1, aH5N6c on Day 22
- Where
- 18 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Seqirus
Avian Influenza, Influenza
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
This is a randomized, un-blinded, Phase II study in males and non-pregnant females, who are in good health, 19 to 64 years of age.
- Conditions
- Avian Influenza, Influenza, Influenza Immunisation
- Trial name
- NCT03318315
- Testing
- AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 4 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Avian Influenza, Influenza Immunisation
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females 19 years and older that is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017 monovalent…
- Trial name
- NCT03312231
- Testing
- AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent
- Where
- 5 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Healthy
Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults
The safety and tolerability of the pandemic A/H5N1 virosomal vaccine formulated with or without the 3rd generation ISCOM™ adjuvant for parenteral administration will be investigated locally and systemically and by using…
- Trial name
- PANFLUVAC (NCT00868218)
- Testing
- Influenza vaccine
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rebecca Cox
Influenza
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged 18 to 64 years
- Trial name
- NCT00695669
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
H5N1 Priming and Boosting Strategies
Severe disease in humans due to bird influenza viruses (H5N1) has led to concern that this virus may result in a widespread outbreak of bird flu.
- Trial name
- NCT00703053
- Testing
- A/Vietnam/1203/04, A/Indonesia/05/05
- Where
- 5 sites in United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00319098
- Testing
- Adjuvanted pandemic influenza candidate vaccine, Fluarix
- Where
- 40 sites in Estonia, France and 5 more
- Volunteers
- 5,075 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age
The present study is designed to evaluate the immunogenicity and safety of a single or double dose of the pandemic influenza candidate vaccine (GSK1562902A), administered following a two-administration schedule (21 days apart) in…
- Trial name
- NCT00397215
- Testing
- Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix
- Where
- 12 sites in Belgium, Italy
- Volunteers
- 437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children
The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.
- Trial name
- NCT01323946
- Testing
- GSK Biologicals' investigational vaccine GSK1562902A
- Where
- 6 sites in Australia, Singapore
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA…
- Trial name
- NCT01147068
- Testing
- 0.5mL Intramuscular Injection
- Where
- 4 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza, Avian Influenza
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths…
- Conditions
- Influenza, Avian Influenza, Severe Influenza
- Trial name
- NCT00298233
- Testing
- Oseltamivir
- Where
- 12 sites in Singapore, Thailand and 1 more
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)